/GTBP
GTBP Stock - GT Biopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.76+3.02%
+$0.02 (+3.02%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.59
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GTBP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.75 – $0.76
TARGET (TP)$0.87
STOP LOSS$0.70
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.53
52W High$4.10
52W Low$0.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,364,000 | $-13,576,000 | $-21,257,000 | $-57,515,000 | $-6,764,000 |
| Net Income | $-13,162,000 | $-7,597,000 | $-20,884,000 | $-58,013,000 | $-28,296,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-6.94 | $-5.64 | $-0.66 | $-2.06 | $-6.45 |
Company Overview
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 1353.3% Upside
Now
$11
Low
$11
Average
$11
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2024 | ROTH MKM | Initiation | Buy | $11 |
Earnings History & Surprises
GTBPBeat Rate
67%
Last 18 quarters
Avg Surprise
-173.3%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.83
Q4 2025
EPS Surprise History
Q2 24
+18.9%
$-2.19vs$-2.70
Q2 24
+21.5%
$-2.12vs$-2.70
Q3 24
+17.0%
$-2.24vs$-2.70
Q4 24
+43.3%
$-1.53vs$-2.70
Q1 25
-7.1%
$-1.66vs$-1.55
Q2 25
-18.8%
$-0.76vs$-0.64
Q3 25
+19.1%
$-0.55vs$-0.68
Q4 25
-118.4%
$-0.83vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 20, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.38 | $-0.83 | -118.4% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.68 | $-0.55 | +19.1% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.64 | $-0.76 | -18.8% | ✗ MISS |
Q1 2025 | Feb 21, 2025 | $-1.55 | $-1.66 | -7.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-2.70 | $-1.53 | +43.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-2.70 | $-2.24 | +17.0% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-2.70 | $-2.12 | +21.5% | ✓ BEAT |
Q2 2024 | Apr 4, 2024 | $-2.70 | $-2.19 | +18.9% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-3.00 | $-1.80 | +40.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-3.00 | $-2.70 | +10.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-4.80 | $-2.40 | +50.0% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.17 | $-5.41 | -3082.4% | ✗ MISS |
Q4 2022 | Oct 31, 2022 | $-3.30 | $-6.61 | -100.3% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-5.41 | $-3.00 | +44.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-6.91 | $-5.11 | +26.0% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-6.31 | $-15.62 | -147.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-6.31 | $-5.11 | +19.0% | ✓ BEAT |
Q3 2021 | Aug 23, 2021 | $-8.41 | $-4.50 | +46.5% | ✓ BEAT |
Latest News
GT Biopharma Advances Potent NK-Cell Therapies As GTB 3650, Is Currently Being Tested In Phase 1 Trials For Patients With Relapsed Or Refractory Acute Myeloid Leukemia
📈 PositiveBenzinga•Nov 19, 2025, 01:09 PM
GT Biopharma Completes Cohort 3 In GTB-3650 Formal Safety Review With No Safety Or Tolerability Issues Observed
📈 PositiveBenzinga•Oct 23, 2025, 01:05 PM
GT Biopharma shares are trading higher after the company announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 for the treatment of relapsed or refractory CD33 expressing hematologic malignancies, is on track.
📈 PositiveBenzinga•Oct 8, 2025, 07:27 PM
EXCLUSIVE: GT Biopharma Tells Benzinga 'Upon successful completion of the Cohort 3 safety assessment, the trial will continue to dose escalate with initiation of Cohort 4 dosing planned by year-end 2025, and flexibility to dose up to 7 cohorts if necessary; additional data updates anticipated in Q1 2026'
➖ NeutralBenzinga•Oct 8, 2025, 12:30 PM
EXCLUSIVE: GT Biopharma Tells Benzinga 'The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the previous two lower-dose cohorts; additional update anticipated by year-end'
📈 PositiveBenzinga•Oct 8, 2025, 12:30 PM
EXCLUSIVE: GT Biopharma Tells Benzinga 'The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date'
📈 PositiveBenzinga•Oct 8, 2025, 12:30 PM
EXCLUSIVE: GT Biopharma Tells Benzinga Co. Provides Enrollment Updates On GT-3650 Phase I Trial In Patients With Relapsed Or Refractory (r/r) CD33 Expressing Hematologic Malignancies
➖ NeutralBenzinga•Oct 8, 2025, 12:30 PM
Frequently Asked Questions about GTBP
What is GTBP's current stock price?
GT Biopharma, Inc. (GTBP) is currently trading at $0.76 per share. The stock has moved +3.02% today.
What is the analyst price target for GTBP?
No analyst price targets are currently available for this stock.
What sector is GT Biopharma, Inc. in?
GT Biopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GTBP's market cap?
GT Biopharma, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does GTBP pay dividends?
No, GT Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
CARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to GTBP for comparison